Supplementary IOL
Colin Kerr
Published: Saturday, April 1, 2017
Rayner has announced that a selection of models in their Sulcoflex range of pseudophakic supplementary IOLs have received Chinese Food and Drug Administration (CFDA) approval.
“After a four-year registration application – the longest in the history of Rayner – the CFDA has confirmed it’s approval of this selection of Sulcoflex IOLs. This innovation has been successfully implanted for 10 years and we are excited about launching it in a market as important as China,” said Rayner’s Commercial Director Cary Dawes.
“China is Rayner’s number one distributor market in terms of size and growth, so to add the Sulcoflex platform to our offering will open up even more growth opportunities,” he said.
www.rayner.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.